Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Pontevedra (44)

2024

  1. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 337-346

  2. Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain)

    Gastroenterologia y Hepatologia

  3. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  4. Recommendations for the future management of thrombocytopenia in patients with liver cirrhosis: A modified RAND/UCLA appropriateness method

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 1, pp. 32-50

  5. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  2. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

  3. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2022

  1. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Fecal incontinence and CRC

    Foundations of Colorectal Cancer (Elsevier), pp. 593-598

  3. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

    Scientific Reports, Vol. 11, Núm. 1

  4. Roadmap to resuming care for liver diseases after coronavirus disease-2019

    Journal of Gastroenterology and Hepatology (Australia), Vol. 36, Núm. 4, pp. 885-892

  5. Sharing knowledge on Hepatology in times of change, or, why you should be on Twitter

    Gastroenterologia y Hepatologia

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  3. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  4. One world, one pandemic, many guidelines: Management of liver diseases during COVID-19

    Gut, Vol. 69, Núm. 8, pp. 1369-1372

  5. Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test

    World Journal of Gastroenterology, Vol. 26, Núm. 1, pp. 70-85

  6. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25